FindTrial
Sign In

A study to check the HIV-1 subtype-specific drug resistance in patients who are failing dolutegravir-based first-line, second-line or third-line regimens - a multiregional study

HIV-1 subtype-specific drug resistance in patients failing dolutegravir-based first-line, second-line or third-line regimens: multiregional study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2024/09/074047
Enrollment
4000
Registered
2024-09-19
Start date
Unknown
Completion date
Unknown
Last updated
2024-10-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: B20- Human immunodeficiency virus [HIV]disease

Interventions

Intervention1: NIL: It is an observation study. Control Intervention1: NIL: It is an observation study.

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: - adults aged 18 years or older - on any DTG-based ART regimen - who develop virologic failure defined as a VL more than 1000 copies per mL single or confirmed measurement, - and have signed the informed consent.

Exclusion criteria

Exclusion criteria: Patients with no virologic failure

Design outcomes

Primary

MeasureTime frame
1. Number of InSTI DRMs as well as DTG drug resistance. 2. Virologic failure.Timepoint: single time point—

Secondary

MeasureTime frame
NilTimepoint: Nil—

Countries

Argentina, Burkina Faso, Cambodia, Cameroon, Congo, Cote d'Ivoire, India, Kenya, Rwanda, Tanzania, Thailand, Uganda

Contacts

Public ContactDr Nagalingeswaran Kumarasamy

Voluntary Health Services Infectious Diseases Medical Centre

kumarasamy@cartcrs.org9176912007

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026